8.53
0.12 (1.43%)
| 前收盘价格 | 8.41 |
| 收盘价格 | 8.35 |
| 成交量 | 5,024 |
| 平均成交量 (3个月) | 21,818 |
| 市值 | 312,964,000 |
| 价格/销量 (P/S) | 38.30 |
| 股市价格/股市净资产 (P/B) | 28.87 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2025 - 3 Mar 2025 |
| 营业利益率 (TTM) | -2,585.09% |
| 稀释每股收益 (EPS TTM) | -5.05 |
| 季度收入增长率 (YOY) | -9.50% |
| 总债务/股东权益 (D/E MRQ) | 58.68% |
| 流动比率 (MRQ) | 0.960 |
| 营业现金流 (OCF TTM) | -69.19 M |
| 杠杆自由现金流 (LFCF TTM) | -40.90 M |
| 资产报酬率 (ROA TTM) | -195.55% |
| 股东权益报酬率 (ROE TTM) | -697.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (AU) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | ANTERIS CDI 1:1 [AVR] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.50 |
|
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 10.51% |
| 机构持股比例 | 39.60% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合